Skip to main content
Top
Published in: CEN Case Reports 4/2020

01-11-2020 | ANCA-Associated Vasculitis | Case Report

A case report of progressive multifocal leukoencephalopathy during steroid treatment for ANCA-associated renal vasculitis

Authors: Takashi Tawara, Hirayasu Kai, Mikiko Kageyama, Tomoki Akiyama, Takahiro Matsunaga, Aki Sakuma, Ryota Ishii, Ryouya Tsunoda, Tetusya Kawamura, Akiko Fujita, Shuzo Kaneko, Naoki Morito, Chie Saito, Joichi Usui, Kunihiro Yamagata

Published in: CEN Case Reports | Issue 4/2020

Login to get access

Abstract

Case report: an 80-year-old woman presented with rapidly progressive glomerulonephritis and was admitted to our hospital. Myeloperoxidase-specific antineutrophil cytoplasmic antibody (MPO-ANCA) was positive. We diagnosed ANCA-associated renal vasculitis (ANCA-RV). Treatment was initiated with intravenous methylprednisolone pulse therapy, followed by prednisolone (PSL) at 30 mg/day. We gradually reduced the PSL dose to 7.5 mg/day over 6 months. At that time, the patient developed disturbances of consciousness which progressed subacutely. MRI revealed regions of patchy white matter with an increased signal on T2-weighted, fluid attenuated inversion recovery (FLAIR) sequences and diffusion-weighted sequences. JC virus DNA was detected in the cerebrospinal fluid (CSF) by polymerase chain reaction (PCR), leading to a diagnosis of progressive multifocal leukoencephalopathy (PML). PML is a rare infectious demyelinating disease of the central nervous system caused by JC virus infection, occurring in highly immunosuppressed individuals such as HIV-infected patients and patients using some biological agents, and having a very poor prognosis. In the present case, PML may have been associated with steroid use, although there are very few case reports of PML in patients taking only steroids. We report progressive multifocal leukoencephalopathy during steroid treatment of ANCA-RV. When patients show progressive disturbance of consciousness during treatment for ANCA-RV, we need to take PML into consideration for differential diagnosis.
Literature
12.
go back to reference Pugnet G, Pagnoux C, Bezanahary H, Ly KH, Vidal E, Guillevin L. Progressive multifocal encephalopathy after cyclophosphamide in granulomatosis with polyangiitis (Wegener) patients: case report and review of literature. Clin Exp Rheumatol. 2013;31(1 Suppl 75):S62–S6464.PubMed Pugnet G, Pagnoux C, Bezanahary H, Ly KH, Vidal E, Guillevin L. Progressive multifocal encephalopathy after cyclophosphamide in granulomatosis with polyangiitis (Wegener) patients: case report and review of literature. Clin Exp Rheumatol. 2013;31(1 Suppl 75):S62–S6464.PubMed
17.
go back to reference Yoshida H, Ohshima K, Toda J, Kusakabe S, Masaie H, Yagi T, et al. Significant improvement following combination treatment with mefloquine and mirtazapine in a patient with progressive multifocal leukoencephalopathy after allogeneic peripheral blood stem cell transplantation. Int J Hematol. 2014;99(1):95–9. https://doi.org/10.1007/s12185-013-1471-0.CrossRefPubMed Yoshida H, Ohshima K, Toda J, Kusakabe S, Masaie H, Yagi T, et al. Significant improvement following combination treatment with mefloquine and mirtazapine in a patient with progressive multifocal leukoencephalopathy after allogeneic peripheral blood stem cell transplantation. Int J Hematol. 2014;99(1):95–9. https://​doi.​org/​10.​1007/​s12185-013-1471-0.CrossRefPubMed
Metadata
Title
A case report of progressive multifocal leukoencephalopathy during steroid treatment for ANCA-associated renal vasculitis
Authors
Takashi Tawara
Hirayasu Kai
Mikiko Kageyama
Tomoki Akiyama
Takahiro Matsunaga
Aki Sakuma
Ryota Ishii
Ryouya Tsunoda
Tetusya Kawamura
Akiko Fujita
Shuzo Kaneko
Naoki Morito
Chie Saito
Joichi Usui
Kunihiro Yamagata
Publication date
01-11-2020
Publisher
Springer Singapore
Published in
CEN Case Reports / Issue 4/2020
Electronic ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-020-00482-w

Other articles of this Issue 4/2020

CEN Case Reports 4/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.